February 27, 2017 / 10:17 AM / 5 months ago

Israel's Pharma Two B raises $30 mln for trial of Parkinson's treatment

1 Min Read

JERUSALEM, Feb 27 (Reuters) -

* Israel-based Pharma Two B, which is developing treatments for Parkinson’s disease, said on Monday it completed a third round of financing for $30 million.

* The company said the funds will be used to complete the final phase III clinical trial needed to register P2B001, its lead combination product for the treatment of Parkinson’s disease.

* The financing was led by Israel Biotech Fund and included biotech investors aMoon and JVC, as well as current investor, Chicago-based JK&B Capital.

* Pharma Two B said P2B001 could potentially help in the early stage of the disease and also be an add-on to Levodopa, which is today a main drug choice. (Reporting by Ari Rabinovitch)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below